Traws Pharma (NASDAQ:TRAW) reported quarterly earnings of $2.09 per share which beat the analyst consensus estimate of $(8.04) by 126 percent. This is a 135.3 percent increase over losses of $(5.92) per share from the same period last year. The company reported quarterly sales of $57.00 thousand which missed the analyst consensus estimate of $60.00 thousand by 5.00 percent. This is a 1.79 percent increase over sales of $56.00 thousand the same period last year.